Arvinas, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2830 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - May 4th, 2025 12:36 pm
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN) - May 2nd, 2025 1:19 pm
Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... - May 2nd, 2025 7:03 am
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates - May 1st, 2025 12:15 pm
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 1st, 2025 11:00 am
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Apr 29th, 2025 2:01 pm
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Apr 28th, 2025 11:00 am
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Apr 28th, 2025 10:45 am
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 2:44 pm
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting - Apr 21st, 2025 11:00 am
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple - Apr 9th, 2025 1:43 pm
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) - Apr 9th, 2025 1:35 pm
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - Apr 4th, 2025 7:38 pm
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Apr 4th, 2025 4:33 pm
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation - Apr 4th, 2025 11:00 am
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Apr 3rd, 2025 11:52 am
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - Mar 27th, 2025 11:00 am
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Mar 19th, 2025 1:35 pm
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Mar 19th, 2025 12:05 am
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength? - Mar 17th, 2025 1:51 pm